El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
El trading conlleva riesgos
Los CFDs son instrumentos complejos y tienen un alto riesgo de perder dinero rápidamente debido al apalancamiento.
Español (Latinoamérica)
CRISPR Therapeutics AG
Cerrado
SectorSalud
56.48 -0.96
Resumen
Variación precio
24h
Mínimo
54.67
Máximo
57.03
Ingresos | -24M -131M |
|---|---|
Ventas | -25K 864K |
Margen de beneficio | -15,117.245 |
Empleados | 393 |
EBITDA | -48M -149M |
Recomendaciones | Comprar |
|---|---|
Estimación a 12 meses | +22.47% upside |
Próximas Ganancias | 4 may 2026 |
|---|
Capitalización de Mercado | 1.1B 5.8B |
|---|---|
Apertura anterior | 57.44 |
Cierre anterior | 56.48 |
Noticias sobre sentimiento de mercado
By Acuity
50%
50%
154 / 351 Clasificación en Healthcare
Puntuación técnica
By Trading Central
Confianza
Very Strong Bearish Evidence
CRISPR Therapeutics AG Gráfico
El rendimiento pasado no es un indicador fiable de resultados futuros.
Noticias Relacionadas
Comparación entre iguales
Cambio de precio
CRISPR Therapeutics AG Esperado
Precio Objetivo
By TipRanks
22.47% repunte
Estimación a 12 meses
Media 70.21 USD 22.47%
Máximo 105 USD
Mínimo 33 USD
De acuerdo con 16 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para CRISPR Therapeutics AG Dist en los últimos 3 meses.
Sentimiento
By Acuity
154 / 351 Clasificación en Salud
Noticias sobre sentimiento de mercado
Neutral
Volatilidad
Por debajo de la media
Volumen de Noticias (RCV)
Por debajo de la media
Finanzas
Gastos de venta y administración
Gastos operativos
Beneficio antes de impuestos
Ventas
Coste de ventas
Beneficio bruto de ventas
Gasto por intereses de deuda
EBITDA
Beneficio operativo
$
Acerca de CRISPR Therapeutics AG
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company's lead product candidate is CASGEVY, an ex vivo CRISPR/Cas9 gene-edited cell therapy for treating patients suffering from transfusion-dependent beta-thalassemia, severe sickle cell disease, and hemoglobinopathies in which a patient's hematopoietic stem and progenitor cells are edited to produce high levels of fetal hemoglobin in red blood cells. It also develops CAR T cell therapies, including CTX112 targeting CD19 and CTX131 targeting CD70 for oncology and autoimmunune indications; CTX310 and CTX320, in vivo gene editing to address the cardiovascular disease by disrupting the validated targets angiopoietin-like protein 3 and lipoprotein; and VCTX211, an allogeneic, gene-edited, hypoimmune stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Live chat